Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

1.2K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.2K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

197
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
197
Angina IV: Management01:26

Angina IV: Management

139
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
139
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

484
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
484
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

135
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
135
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

131
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
131

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Role of Nanoplastics in Decreasing the Intestinal Microbiome Ratio: A Review of the Scope of Polystyrene.

Toxics·2025
Same author

Gut Microbiome: Profound Implications for Diet and Disease.

Nutrients·2019
Same author

Refining amino acid hydrophobicity for dynamics simulation of membrane proteins.

PeerJ·2018
Same author

Model parameters for simulation of physiological lipids.

Journal of computational chemistry·2016
Same author

Balancing bond, nonbond, and gō-like terms in coarse grain simulations of conformational dynamics.

Methods in molecular biology (Clifton, N.J.)·2013
Same author

Peptide backbone sampling convergence with the adaptive biasing force algorithm.

The journal of physical chemistry. B·2012

Related Experiment Video

Updated: Nov 28, 2025

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

14.9K

Statin Treatment in Specific Patient Groups: Role for Improved Cardiovascular Risk Markers.

Alyssa M B White1, Hillary R Mishcon1, John L Redwanski2

  • 1Department of Pharmaceutical Sciences and Administration, University of New England, Portland, ME 04103, USA.

Journal of Clinical Medicine
|November 25, 2020
PubMed
Summary

Statins effectively lower LDL cholesterol for secondary prevention. However, their benefit in primary prevention, especially for older adults, requires careful risk assessment using advanced tools like CAC scores to personalize treatment and minimize side effects.

Keywords:
cardiovascular diseasecardiovascular risk calculatorscoenzyme Qcoronary artery calcificationgeriatricslipoprotein subfractionslow-density lipoprotein cholesterolprimary preventionrisk biomarkersstatins

More Related Videos

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
04:30

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

Published on: May 14, 2013

26.0K

Related Experiment Videos

Last Updated: Nov 28, 2025

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

14.9K
A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
04:30

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

Published on: May 14, 2013

26.0K

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology
  • Preventive Cardiology

Background:

  • Statin therapy is well-established for secondary prevention of atherosclerotic cardiovascular disease (ASCVD).
  • Evidence for statin efficacy in primary prevention, low-risk individuals, and the elderly (65+) is less robust.
  • Low-density lipoprotein (LDL) cholesterol has been a primary target, but its relationship with mortality weakens with age.

Purpose of the Study:

  • To evaluate statin efficacy across diverse patient subsets, including age, diabetes, ASCVD history, and coronary artery calcium (CAC) status.
  • To discuss the evolving understanding of cholesterol's role in mortality and introduce superior ASCVD risk markers.
  • To emphasize the need for improved risk assessment tools for personalized statin therapy decisions.

Main Methods:

  • Comparative analysis of statin efficacy in different patient demographics and risk profiles.
  • Review of current cardiovascular risk calculators and their limitations, particularly in older adults.
  • Exploration of advanced risk stratification tools, including coronary artery calcium (CAC) scoring.
  • Discussion of adjunctive therapies, such as coenzyme Q forms, for optimizing outcomes.

Main Results:

  • Traditional risk calculators may overestimate ASCVD risk, especially in the very old.
  • CAC scores can effectively stratify statin benefit, guiding treatment decisions.
  • Statin benefits are reduced and adverse effects, like musculoskeletal issues, are amplified in adults over 75.

Conclusions:

  • Personalized, evidence-based approaches utilizing robust risk estimators are crucial for optimizing statin therapy.
  • Improved risk assessment identifies specific populations who benefit most from statins, balancing efficacy and potential harms.
  • The focus is shifting towards tailored interventions to reduce cardiovascular events and mortality.